4Shah IM, Breslin CJ, Wittayanarakul K, etal. Pharmaeogenetics of cytochrome P450 2D6 : A translational medicine perspective the open[J]. Conference Proceedings J, 2010,1 ( 1 ) : 103-108.
5Zhou SF. PoIymorphism of human cytochrome P450 2D6 and its clinical significance : Part I[J]. Clin pharmaeokinet, 2009,48 (11) : 689-723.
6Johansson I, Ingelman-Sundberg M. Genetic polymorphism and toxicology with emphasis on cytochrome P450[J]. Toxicological Sciences, 2011,120(1) : 1-13.
7Brodde OE, Kroemer HK. Drug-drug interactions of β-adrenoeeptor blockers[J]. Arzneimittelforschung, 2003,53(12) : 814-822.
8Wuttke H, Rau T, Heide R, et al. Increased frequency of cytochrome P450 2D6 poor metabolizers among patients with meto- prolol associated adverse effects[J]. Clin Pharmacol Ther, 2002, 72(4) :429-437.
9Mehvar R. Stereospecific pharmacokinetics and pharmacodynam- ics of beta-adrenergic blockers in humans[J]. J Pharm Pharmaceut Sci,2001,4(2) :185-200.
10Bijl MJ, Visser LE, Sehaik RV, et al. Genetic variation in the CYP2D6 gene is associated with a lower heart rate and blood pres- sure in β-blocker users [J]. Clinical Pharmac & Therapeutics, 2009,85 (1) : 45-50.
7Rau T, Heide R, Bergmann K, et al. Effect of the CYP2D6 gen- otype on metoprolol metabolism persists'during long-term treat- ment[J]. Pharmacogenetics,2002,12(6) :465-472.
8Wellstein A, Palm D,Belz GG, etal. Reduction of exercise tach-ycardia in man after propranolol, atenolol and bisoprolol in com- parison to beta-adrenoceptor occupancy[J]. Eur Heart J, 1987,8 (Suppl M) :S3-8.
9Munzel T, Gori T. Nebivolol: the somewhat-different 2-adrener- gie receptor blocker[J]. J Am Coll Cardiol, 2009,54 (4) : 1491- 1499.
